(397bo) Evaluation Of A New Method For Encapsulating Two Drugs In PLGA Nanoparticles: Physical-Chemical Charaterization | AIChE

(397bo) Evaluation Of A New Method For Encapsulating Two Drugs In PLGA Nanoparticles: Physical-Chemical Charaterization

Authors 

Carranza Oropeza, M. V. - Presenter, Polytechnic School of the University of São Paulo
Español, L., São Paulo University
Giudici, R., University of São Paulo
Prado, M. A., Sao Paulo University



Currently one of the rheumatic diseases that most affects the world population is rheumatoid arthritis (RA), systemic disease, whose main clinical manifestation is chronic inflammation of the synovial membrane and deformation. Approximately 1-2% of the adult population has rheumatoid arthritis, focusing mainly in the elderly. Brazil has approximately 14.1 million of elderly people, and for 2025 they will grown 16 times. In this sense, many researches are developed in different parts of the world to find a more efficient alternative for the treatment this disease.

This research shows the development of a method for encapsulation of two anti-inflammatory drugs, in order to increase their efficiency in the treatment of that disease. The method involves the preparation of nanoparticles (NPs) of the spherical core-shell type morphology; the core is formed by one Non Steroidal Anti-Inflammatory Drug (NSAID) and a glucocorticoid, and the shell casing is a biocompatible polymer PLGA. The physical chemical characterization of the nanoparticles was performed considering the morphological analysis by using a scanning electron microscopy; particle size by dynamic light scattering using a photon correlation espectrometer Coulter NP4 Plus; the load surface using a device for measuring the zeta potential and the thermal analysis by using a calorimeter differential scanning (DSC).

This system loader is an optimal alternative because it has advantages such as: allows modulation of the release of molecules with different physicochemical characteristics, the drug release is more specific and controlled, reduces local and systemic adverse effects, improves treatment effectiveness and reduces costs for the treatment of rheumatoid arthritis.